Olodaterol
| Evidence Level: L4 | Predicted Indications: 2 |
Table of Contents
Olodaterol: From Chronic Obstructive Pulmonary Disease to Bronchitis
One-Sentence Summary
Olodaterol is a once-daily long-acting β2-agonist (LABA) originally used to treat chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may be effective for bronchitis, but this is supported by 0 clinical trials and only 2 publications, both focused on COPD rather than bronchitis itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic obstructive pulmonary disease (COPD) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on the established pharmacology of the drug class, olodaterol is a long-acting β2-agonist. It activates β2-adrenoceptors, raises intracellular cAMP and relaxes airway smooth muscle, producing sustained bronchodilation.
Chronic bronchitis is a recognised phenotype of COPD, the drug's original indication. The very high TxGNN score (0.998) therefore largely reflects overlap with the existing COPD indication rather than a novel repurposing signal. Acute bronchitis would not be expected to benefit from a LABA in the same way, because bronchodilation is not the main treatment goal there.
In short, the prediction is plausible for chronic bronchitis within COPD. It is not a strong signal for a genuinely new use.
Clinical Trial Evidence
Currently no related clinical trials registered for bronchitis.
Note: Many trials exist for the closely related category "obstructive lung disease" (mainly COPD, including several completed Phase 3 studies of olodaterol alone and with tiotropium). These support the existing COPD use rather than bronchitis as a separate indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27354040 | 2016 | Review | Am J Health Syst Pharm | Reviews the pharmacology, pharmacokinetics, efficacy and safety of once-daily olodaterol in COPD |
| 25515181 | 2015 | Guideline | Basic Clin Pharmacol Toxicol | Finnish national guideline on diagnosis and pharmacotherapy of stable COPD, intended mainly for primary care |
Neither publication directly evaluates olodaterol in bronchitis.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2494027 | Spiolto Respimat | Solution for inhalation, 2.5 mcg with olodaterol 2.5 mcg | Not stated (authorization status: cancelled) |
Safety Considerations
- Drug Interactions: 326 known interactions are recorded, all of the ones listed here at moderate level. Examples include:
- Sympathomimetics: epinephrine (including ophthalmic and topical forms), ephedrine, phentermine, diethylpropion and fenfluramine
- QT-relevant agents: clarithromycin, cisapride, dolasetron, palonosetron and granisetron
- Others: famotidine, loperamide, canagliflozin, ertugliflozin, semaglutide and albiglutide
- Class consideration: LABA monotherapy is not recommended in asthma because of safety concerns. Concomitant beta-blockers, QT-prolonging agents and other sympathomimetics should be reviewed.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials and only two COPD-focused publications support bronchitis. The high prediction score mostly reflects overlap with the approved COPD indication. The only New Zealand authorization has been cancelled.
To proceed, the following is needed:
- Clarify whether the target is chronic bronchitis (already covered by COPD) or acute bronchitis (little mechanistic rationale)
- Evidence directly evaluating olodaterol in bronchitis
- Detailed mechanism of action data
- Package insert warnings and contraindications from Medsafe
- Confirmation of current product availability in New Zealand
- A review plan for drug interactions, particularly beta-blockers, QT-prolonging agents and sympathomimetics
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.